NanoBio Corporation to Present Preclinical Data on its Nanoemulsion Adjuvanted Intranasal RSV Vaccine and Novel Inhaled Cystic Fibrosis Therapy at 52nd Annual ICAAC Meeting

ANN ARBOR, Mich.--(BUSINESS WIRE)--NanoBio® Corporation announced today it will present data from two separate preclinical studies at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting currently underway in San Francisco.